A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma
Launched by SOTIRIA GENERAL HOSPITAL · Nov 8, 2018
Trial Information
Current as of August 11, 2025
Unknown status
Keywords
ClinConnect Summary
A multi-centre, prospective, observational study of continuous patients who fulfil the definition of severe asthma and the criteria for mepolizumab (nucala; GSK) therapy. Patients have their daily physical activity recorded using triaxial accelerometry (DynaPort MoveMonitor; McRoberts) prior to treatment, and at 6 and 12 months of mepolizumab therapy (100 mg subcutaneously once every 4 weeks).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Severe asthma
- • 2. Criteria for mepolizumab therapy: blood eosinophils ≥150 cells/μL at screening or ≥300 cells/μL in the past 12 months.
- • Exclusion Criteria: Comorbidities limiting physical activity
About Sotiria General Hospital
Sotiria General Hospital, a leading medical institution in Athens, Greece, is dedicated to advancing healthcare through innovative clinical research and trials. With a strong focus on patient-centered care, the hospital collaborates with multidisciplinary teams of healthcare professionals to conduct high-quality studies that contribute to medical knowledge and improve treatment outcomes. Committed to ethical standards and regulatory compliance, Sotiria General Hospital aims to enhance the quality of life for patients while fostering scientific discoveries that drive progress in various fields of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Athens, , Greece
Patients applied
Trial Officials
Marios Panagiotou, MD
Principal Investigator
Sotiria General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials